|
業務類別
|
Biotechnology |
|
業務概覽
|
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine,is its first commercialized product. |
| 公司地址
| An der Goldgrube 12, Mainz, RP, DEU, D-55131 |
| 電話號碼
| +49 613190840 |
| 傳真號碼
| +49 61319084390 |
| 公司網頁
| https://www.biontech.de |
| 員工數量
| 6772 |
| Mr. James Ryan, PhD |
Chief Legal Officer and Chief Business Officer |
歐元 550.00K |
10/03/2026 |
| Ms. Annemarie Hanekamp |
Chief Commercial Officer |
歐元 550.00K |
10/03/2026 |
| Mr. Ramón Zapata |
Chief Financial Officer |
-- |
10/03/2026 |
| Professor Ugur Sahin, M.D. |
Chief Executive Officer |
歐元 700.00K |
10/03/2026 |
| Dr. Sierk Poetting, PhD |
Chief Operating Officer |
歐元 550.00K |
10/03/2026 |
| Dr. Ozlem Tureci, M.D. |
Chief Medical Officer |
歐元 469.00K |
10/03/2026 |
| Ms. Kylie Jimenez |
Chief People Officer |
-- |
10/03/2026 |
|
|
| Baroness Nicola Blackwood |
Member of the Supervisory Board |
10/03/2026 |
| Dr. Ulrich Wandschneider, PhD |
Deputy Chairman of the Supervisory Board |
10/03/2026 |
| Mr. Helmut Jeggle |
Chairman of the Supervisory Board |
10/03/2026 |
| Mr. Michael Motschmann |
Member of the Supervisory Board |
10/03/2026 |
| Professor Rudolf Staudigl, PhD |
Member of the Supervisory Board |
10/03/2026 |
| Professor Anja Morawietz, PhD |
Member of the Supervisory Board |
10/03/2026 |
|
|
|
|
